Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 20 October, 2009 and appeared in  Issue 491Cardiovascular Health

New Definition of Metabolic Syndrome

A new joint statement from a number of professional organizations has identified specific criteria for the clinical diagnosis of metabolic syndrome, tightening up the definition, which previously differed from one organization to the next.

Advertisement

The statement, includes the participation of the International Diabetes Federation (IDF), the National Heart, Lung, and Blood Institute (NHLBI), the World Heart Federation, the International Atherosclerosis Society, and the American Heart Association (AHA) and is an attempt to eliminate some of the confusion regarding how to identify patients with the syndrome.

Dr. Robert Eckel (University of Colorado, Denver), one of the authors of the new statement, reported that, "This paper represents an attempt to make the definition global. The IDF definition and the [National Cholesterol Education Program Adult Treatment Panel] ATP III definition have been the two that have been utilized most frequently, and now the different organizations -- the IDF, the International Atherosclerosis Society, the NHLBI, and the AHA -- have all signed on to a single definition. I think that's a step forward in terms of not continuing to confuse people who are working in this field."

Specifically, the new metabolic-syndrome definition streamlines previous differences related to abdominal obesity as defined by measurements in waist circumference. Substantial disparities existed between the previous IDF and the ATP III definitions of what constituted an excessively large waist circumference, by as much as 8 cm between the two groups, but these have been amended. Now, the criteria for elevated waist circumference are based on population- and country-specific definitions, which, although streamlined, do leave some work to be done, said Eckel.

"The problem that still exists is that regional differences around the world may be substantial in terms of what waist circumference confers additional risk for heart disease and diabetes," he said. "The new definition relies on different geographic regions, or different countries, to drill down into their own databases in terms of relating waist circumference to risk." Eckel noted that the IDF previously considered elevations in waist circumference mandatory when defining metabolic syndrome, although the ATP III did not. Now, waist circumference is just one of five criteria that physicians can use when diagnosing metabolic syndrome. Patients with three of the five criteria -- including elevated waist circumference, elevated triglycerides, reduced HDL-cholesterol levels, elevated blood pressure, and elevated fasting-glucose levels -- are considered to have the syndrome.

Criteria for Clinical Diagnosis of the Metabolic Syndrome

 

Measure
Categorical cut points

 

Elevated waist circumference

 

Population- and country-specific definitions

 

Elevated triglycerides (drug treatment for elevated triglycerides is an alternate indicator)

>150 mg/dL

 

Reduced HDL cholesterol (drug treatment for reduced HDL cholesterol is an alternate indicator)

<40 mg/dL for males and <50 mg/dL for females

 

Elevated blood pressure (drug treatment for elevated blood pressure is an alternate indicator)

Systolic >130 mm Hg and/or diastolic >85 mm Hg

 

Elevated fasting glucose (drug treatment for elevated glucose is an alternate indicator)

>100 mg/dL

Notably absent from the joint statement is the American Diabetes Association. There are unresolved scientific issues between the ADA and other associations, including the AHA, regarding the metabolic syndrome. Specifically, the ADA, as well as the European Association for the Study of Diabetes(EASD), objected to the manner in which the metabolic syndrome was characterized as a risk factor for heart disease or diabetes, arguing that there was no need to diagnose a patient with the syndrome because emphasis should be placed on aggressively treating the individual risk factors. In 2005, the ADA and EASD issued their own joint statement calling for a critical appraisal of the metabolic syndrome, its designation as a syndrome, and its clinical utility.

Eckel said the IDF, AHA, NHLBI, and others began working on the new metabolic syndrome definition in 2008 and that they simply went ahead without ADA participation. He stressed the metabolic syndrome is not a disease but simply a clustering of risk factors. The original intention of identifying the syndrome was simply to draw clinicians' and the public's attention to the importance of a high-quality lifestyle, and the metabolic syndrome is never meant to be used as a predictor of heart disease or diabetes risk.

Circulation Oct. 5, 2009; 120:1640-1645. Abstract
 

 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 20 October, 2009 and appeared in  Issue 491Cardiovascular Health

Past five issues: Diabetes Clinical Mastery Series Issue 85 | Issue 626 | Special Edition - Getting Patients on Track | Diabetes Clinical Mastery Series Issue 84 | Issue 625 |

2012 Most Popular Articles:

ADA/EASD Issue New Hyperglycemia Management Guidelines
Posted April 26, 2012
Type 2 More Dangerous in Children
Posted May 03, 2012
It’s the Variety of Fruit-and-Veggie That Lower Diabetes Risk
Posted May 03, 2012
Questioning Carbohydrate Restriction in Diabetes Management
Posted May 18, 2012
Ultra-Long-Acting Insulin Degludec, Two New Studies
Posted April 26, 2012
Eating Low Glycemic Index Foods at Breakfast Can Control Blood Sugar throughout the Day
Posted April 18, 2012
Metformin May Treat a Leading Cause of Blindness
Posted May 10, 2012
A Candy Treatment that Fights Diabetes and May Replace TZD's?
Posted May 10, 2012
Metformin May Not Be the Golden Pill After All for Treating Type 2 Diabetes
Posted April 18, 2012
Doubts Over Long Term Effectiveness of Group Education for Diabetes Patients
Posted May 03, 2012

See more most popular…


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Marilyn Porter, RD, CDE | Melissa Diane Smith | Paul Chous, M.A., OD | Philip A. Wood PhD | Sheri R. Colberg PhD | Sherri Shafer | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |
 
Diabetes In Control Advertisers
 
 
Cast Your Vote
Now that once-weekly GLP-1 is available, which product are you recommending for your type 2 patients?

Navigate Diabetes In Control
Announcement:



Search Articles On Diabetes In Control